SEC Filings

Form S-1/A
VITAE PHARMACEUTICALS, INC filed this Form S-1/A on 09/22/2014
Document Outline
Entire Document (6882.9 KB)
Subdocument 1 - S-1/A - S-1/A
Page 1 - As filed with the Securities and Exchange Commission on September 22, 2014
Page 2 - Preliminary Prospectus
Page 3 - TABLE OF CONTENTS
Page 4 - PROSPECTUS SUMMARY
Page 5 - Our Most Advanced Product Candidates
Page 6 - VTP-37948
Page 7 - Our Collaborations
Page 8 - Our Strategy
Page 9 - Corporate Information
Page 10 - N/A
Page 11 - The Offering
Page 12 - N/A
Page 13 - SUMMARY FINANCIAL DATA
Page 14 - N/A
Page 15 - RISK FACTORS
Page 16 - We will require substantial additional financing to achieve our goals, and a failure to obtain this
Page 17 - Raising additional capital may cause dilution to our existing stockholders, restrict our operations
Page 18 - Our ability to use net operating loss and tax credit carryforwards and certain built-in losses to re
Page 19 - Risks Related to the Clinical Development and Regulatory Approval of Our Product Candidates
Page 20 - Clinical failure may occur at any stage of clinical development, and because our product candidates
Page 21 - If we or our partners fail to obtain regulatory approval in jurisdictions outside the United States,
Page 22 - We and BI rely on third parties to conduct preclinical studies and clinical trials for our product c
Page 23 - We intend to rely on third-party manufacturers, including BI with respect to VTP-34072 and VTP-37948
Page 24 - We may not be successful in establishing and maintaining additional strategic partnerships, which co
Page 25 - N/A
Page 26 - Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecut
Page 27 - Third-party claims of intellectual property infringement or misappropriation may prevent or delay ou
Page 28 - We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, wh
Page 29 - We may need to license certain intellectual property from third parties, and such licenses may not b
Page 30 - Our reliance on third parties requires us to share our trade secrets, which increases the possibilit
Page 31 - If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent terms and o
Page 32 - Coverage and reimbursement may be limited or unavailable in certain market segments for our product
Page 33 - The impact of recent healthcare reform legislation and other changes in the healthcare industry and
Page 34 - We face substantial competition, which may result in others discovering, developing or commercializi
Page 35 - Our product candidates may cause undesirable side effects or have other properties that delay or pre
Page 36 - Risks Related to Our Business and Industry
Page 37 - Our employees, independent contractors, principal investigators, CROs, consultants, commercial partn
Page 38 - N/A
Page 39 - We may encounter difficulties in managing our growth and expanding our operations successfully.
Page 40 - If product liability lawsuits are brought against us, we may incur substantial liabilities and may b
Page 41 - Our internal computer systems, or those of our development partners, third-party clinical research o
Page 42 - Risks Related to Our Common Stock and this Offering
Page 43 - Our quarterly operating results may fluctuate significantly.
Page 44 - You will suffer immediate and substantial dilution in the net tangible book value of the common stoc
Page 45 - We do not intend to pay dividends on our common stock, and, consequently, your ability to achieve a
Page 46 - We are an emerging growth company, and the reduced reporting requirements applicable to emerging gro
Page 47 - If we fail to maintain proper and effective internal control over financial reporting in the future,
Page 48 - N/A
Page 49 - INFORMATION REGARDING FORWARD-LOOKING STATEMENTS
Page 50 - INDUSTRY AND MARKET DATA
Page 51 - USE OF PROCEEDS
Page 52 - DIVIDEND POLICY
Page 53 - CAPITALIZATION
Page 54 - N/A
Page 55 - DILUTION
Page 56 - N/A
Page 57 - SELECTED FINANCIAL DATA
Page 58 - N/A
Page 59 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF
Page 60 - Strategic Partnerships
Page 61 - B-site Amyloid Precursor Protein-Cleaving Enzyme Inhibitors with BI
Page 62 - Financial Operations Overview
Page 63 - Milestone Revenue
Page 64 - N/A
Page 65 - RORgt
Page 66 - Contour and Technology Development
Page 67 - Revenue Recognition
Page 68 - Accrued Clinical and Preclinical Expenses
Page 69 - Stock-Based Compensation
Page 70 - Valuation of Privately-Held-Company Equity Securities Issued as Compensation
Page 71 - Results of Operations
Page 72 - General and Administrative.
Page 73 - General and Administrative.
Page 74 - Cash Flows
Page 75 - Comparison of Years Ended December 31, 2013 and 2012
Page 76 - Plan of Operation
Page 77 - Contractual Obligations and Commitments
Page 78 - Recently Adopted Accounting Standards
Page 79 - BUSINESS
Page 80 - N/A
Page 81 - in vivo
Page 82 - Our Strategy
Page 83 - Continue investing in technology, people and intellectual property.
Page 84 - Cortisol in Metabolic Disease
Page 85 - Market Opportunity
Page 86 - Preclinical Data
Page 87 - VTP-37948 Targeting b-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE) for Alzheimer's Diseas
Page 88 - BACE as a Target in Alzheimer's Disease
Page 89 - Market Opportunity
Page 90 - Figure 5: Rats brain tissue assayed for levels of Ab and concentrations of VTP-37948. The various sy
Page 91 - IL-17 and Th17 Cells in Autoimmunity
Page 92 - RORgt as a Target in Autoimmunity
Page 93 - Market Opportunity
Page 94 - Human Whole Blood Assay
Page 95 - Left
Page 96 - Development Plans
Page 97 - Inflammation in ACS
Page 98 - Market Opportunity
Page 99 - ABCA1 mRNA in Human Skin Fibroblasts
Page 100 - Figure 17: Cynomolgus monkeys were dosed once-a-day for 14 days with VTP-38443. Levels of mRNA for A
Page 101 - Development Plans
Page 102 - Figure 19: Depiction of the composition and architecture of the epidermis.
Page 103 - Preclinical Data
Page 104 - Figure 21: VTP-38543 induced genes critical for lipid transport and lipid synthesis in skin.
Page 105 - Inhibition of IL-6 Secretion by THP-1 Macrophages
Page 106 - Immuno-Oncology Program
Page 107 - Contour Discovery Process
Page 108 - de novo
Page 109 - Figure 27: Time to develop a novel chemistry solution and achieve animal proof-of-concept.
Page 110 - Collaborations
Page 111 - BACE
Page 112 - Intellectual Property
Page 113 - 11b HSD1 Type 2 Diabetes:
Page 114 - Competition
Page 115 - Manufacturing
Page 116 - Government Regulation and Product Approval
Page 117 - Phase 1.
Page 118 - Post-approval Requirements
Page 119 - Regulation Outside of the United States
Page 120 - Other Healthcare Laws
Page 121 - N/A
Page 122 - Coverage and Reimbursement
Page 123 - Employees
Page 124 - MANAGEMENT
Page 125 - Arthur Fratamico, R.Ph.
Page 126 - Charles W. Newhall, III
Page 127 - Board Composition
Page 128 - Director Independence
Page 129 - Compensation Committee
Page 130 - Director Compensation
Page 131 - N/A
Page 132 - EXECUTIVE COMPENSATION
Page 133 - Equity Compensation
Page 134 - Outstanding Equity Awards as of December 31, 2013
Page 135 - N/A
Page 136 - Severance Benefits
Page 137 - Retirement Benefits
Page 138 - Letter Agreement with New Chief Business Officer
Page 139 - Administration.
Page 140 - Corporate Transactions.
Page 141 - Changes in Capitalization.
Page 142 - Administration.
Page 143 - Changes in Capitalization.
Page 144 - Changes in Capitalization.
Page 145 - Administration.
Page 146 - 2014 Employee Stock Purchase Plan
Page 147 - CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Page 148 - Employment Agreements
Page 149 - PRINCIPAL STOCKHOLDERS
Page 150 - N/A
Page 151 - N/A
Page 152 - N/A
Page 153 - DESCRIPTION OF CAPITAL STOCK
Page 154 - Restricted Stock Units
Page 155 - Certificate of Incorporation and Bylaws
Page 156 - Exclusive Jurisdiction for Certain Actions
Page 157 - SHARES ELIGIBLE FOR FUTURE SALE
Page 158 - Rule 701
Page 159 - MATERIAL UNITED STATES TAX CONSIDERATIONS TO NON-U.S. HOLDERS
Page 160 - Distributions on Our Common Stock
Page 161 - U.S. Federal Estate Tax
Page 162 - N/A
Page 163 - UNDERWRITING
Page 164 - Commissions and Discounts
Page 165 - N/A
Page 166 - NASDAQ Market Listing
Page 167 - Discretionary Sales
Page 168 - Notice to Residents of the United Kingdom
Page 169 - Notice to Residents of the Netherlands
Page 170 - N/A
Page 171 - LEGAL MATTERS
Page 172 - VITAE PHARMACEUTICALS, INC.
Page 173 - Report of Independent Registered Public Accounting Firm
Page 174 - Balance Sheets
Page 175 - Statements of Operations
Page 176 - Statements of Comprehensive Income
Page 177 - Vitae Pharmaceuticals, Inc.
Page 178 - Statements of Cash Flows
Page 179 - 1. Organization
Page 180 - Notes to the Financial Statements (Continued)
Page 181 - Notes to the Financial Statements (Continued)
Page 182 - Notes to the Financial Statements (Continued)
Page 183 - Notes to the Financial Statements (Continued)
Page 184 - Notes to the Financial Statements (Continued)
Page 185 - Notes to the Financial Statements (Continued)
Page 186 - Notes to the Financial Statements (Continued)
Page 187 - Notes to the Financial Statements (Continued)
Page 188 - Notes to the Financial Statements (Continued)
Page 189 - Notes to the Financial Statements (Continued)
Page 190 - Notes to the Financial Statements (Continued)
Page 191 - Notes to the Financial Statements (Continued)
Page 192 - Notes to the Financial Statements (Continued)
Page 193 - Notes to the Financial Statements (Continued)
Page 194 - Notes to the Financial Statements (Continued)
Page 195 - Notes to the Financial Statements (Continued)
Page 196 - Notes to the Financial Statements (Continued)
Page 197 - Notes to the Financial Statements (Continued)
Page 198 - Notes to the Financial Statements (Continued)
Page 199 - Notes to the Financial Statements (Continued)
Page 200 - Notes to the Financial Statements (Continued)
Page 201 - Notes to the Financial Statements (Continued)
Page 202 - Notes to the Financial Statements (Continued)
Page 203 - Notes to the Financial Statements (Continued)
Page 204 - Notes to the Financial Statements (Continued)
Page 205 - Condensed Balance Sheets
Page 206 - Unaudited Condensed Statements of Operations
Page 207 - Unaudited Condensed Statements of Comprehensive Loss
Page 208 - Unaudited Condensed Statements of Cash Flows
Page 209 - Notes to Unaudited Condensed Financial Statements
Page 210 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 211 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 212 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 213 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 214 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 215 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 216 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 217 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 218 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 219 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 220 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 221 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 222 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 223 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 224 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 225 - 5,000,000 Shares
Page 226 - PART II
Page 227 - Item 15. Recent Sales of Unregistered Securities
Page 228 - Item 16. Exhibits and Financial Statement Schedules
Page 229 - provided
Page 230 - SIGNATURES
Page 231 - N/A
Page 232 - EXHIBIT INDEX
Page 233 - N/A
Subdocument 2 - EX-5.1 - EX-5.1
Page 1 - Exhibit 5.1
Subdocument 3 - EX-10.6 - EX-10.6
Page 1 - Exhibit 10.6
Page 2 - CONFIDENTIAL TREATMENT REQUESTED
Page 3 - CONFIDENTIAL TREATMENT REQUESTED
Page 4 - CONFIDENTIAL TREATMENT REQUESTED
Page 5 - CONFIDENTIAL TREATMENT REQUESTED
Page 6 - CONFIDENTIAL TREATMENT REQUESTED
Page 7 - CONFIDENTIAL TREATMENT REQUESTED
Page 8 - CONFIDENTIAL TREATMENT REQUESTED
Page 9 - CONFIDENTIAL TREATMENT REQUESTED
Page 10 - CONFIDENTIAL TREATMENT REQUESTED
Page 11 - CONFIDENTIAL TREATMENT REQUESTED
Page 12 - CONFIDENTIAL TREATMENT REQUESTED
Page 13 - CONFIDENTIAL TREATMENT REQUESTED
Page 14 - CONFIDENTIAL TREATMENT REQUESTED
Page 15 - CONFIDENTIAL TREATMENT REQUESTED
Page 16 - CONFIDENTIAL TREATMENT REQUESTED
Page 17 - CONFIDENTIAL TREATMENT REQUESTED
Page 18 - CONFIDENTIAL TREATMENT REQUESTED
Page 19 - CONFIDENTIAL TREATMENT REQUESTED
Page 20 - CONFIDENTIAL TREATMENT REQUESTED
Page 21 - CONFIDENTIAL TREATMENT REQUESTED
Page 22 - CONFIDENTIAL TREATMENT REQUESTED
Page 23 - CONFIDENTIAL TREATMENT REQUESTED
Page 24 - CONFIDENTIAL TREATMENT REQUESTED
Page 25 - CONFIDENTIAL TREATMENT REQUESTED
Page 26 - CONFIDENTIAL TREATMENT REQUESTED
Page 27 - CONFIDENTIAL TREATMENT REQUESTED
Page 28 - CONFIDENTIAL TREATMENT REQUESTED
Page 29 - CONFIDENTIAL TREATMENT REQUESTED
Page 30 - CONFIDENTIAL TREATMENT REQUESTED
Page 31 - CONFIDENTIAL TREATMENT REQUESTED
Page 32 - CONFIDENTIAL TREATMENT REQUESTED
Page 33 - CONFIDENTIAL TREATMENT REQUESTED
Page 34 - CONFIDENTIAL TREATMENT REQUESTED
Page 35 - CONFIDENTIAL TREATMENT REQUESTED
Page 36 - CONFIDENTIAL TREATMENT REQUESTED
Page 37 - CONFIDENTIAL TREATMENT REQUESTED
Page 38 - CONFIDENTIAL TREATMENT REQUESTED
Page 39 - CONFIDENTIAL TREATMENT REQUESTED
Page 40 - CONFIDENTIAL TREATMENT REQUESTED
Page 41 - CONFIDENTIAL TREATMENT REQUESTED
Page 42 - CONFIDENTIAL TREATMENT REQUESTED
Page 43 - CONFIDENTIAL TREATMENT REQUESTED
Page 44 - CONFIDENTIAL TREATMENT REQUESTED
Page 45 - CONFIDENTIAL TREATMENT REQUESTED
Page 46 - CONFIDENTIAL TREATMENT REQUESTED
Page 47 - CONFIDENTIAL TREATMENT REQUESTED
Page 48 - CONFIDENTIAL TREATMENT REQUESTED
Page 49 - CONFIDENTIAL TREATMENT REQUESTED
Page 50 - CONFIDENTIAL TREATMENT REQUESTED
Page 51 - CONFIDENTIAL TREATMENT REQUESTED
Page 52 - CONFIDENTIAL TREATMENT REQUESTED
Page 53 - CONFIDENTIAL TREATMENT REQUESTED
Page 54 - CONFIDENTIAL TREATMENT REQUESTED
Page 55 - CONFIDENTIAL TREATMENT REQUESTED
Page 56 - CONFIDENTIAL TREATMENT REQUESTED
Page 57 - CONFIDENTIAL TREATMENT REQUESTED
Page 58 - CONFIDENTIAL TREATMENT REQUESTED
Page 59 - CONFIDENTIAL TREATMENT REQUESTED
Page 60 - CONFIDENTIAL TREATMENT REQUESTED
Page 61 - CONFIDENTIAL TREATMENT REQUESTED
Page 62 - CONFIDENTIAL TREATMENT REQUESTED
Page 63 - CONFIDENTIAL TREATMENT REQUESTED
Page 64 - CONFIDENTIAL TREATMENT REQUESTED
Page 65 - CONFIDENTIAL TREATMENT REQUESTED
Page 66 - CONFIDENTIAL TREATMENT REQUESTED
Page 67 - CONFIDENTIAL TREATMENT REQUESTED
Page 68 - CONFIDENTIAL TREATMENT REQUESTED
Page 69 - CONFIDENTIAL TREATMENT REQUESTED
Page 70 - CONFIDENTIAL TREATMENT REQUESTED
Page 71 - CONFIDENTIAL TREATMENT REQUESTED
Page 72 - CONFIDENTIAL TREATMENT REQUESTED
Page 73 - CONFIDENTIAL TREATMENT REQUESTED
Page 74 - CONFIDENTIAL TREATMENT REQUESTED
Page 75 - CONFIDENTIAL TREATMENT REQUESTED
Page 76 - CONFIDENTIAL TREATMENT REQUESTED
Page 77 - CONFIDENTIAL TREATMENT REQUESTED
Page 78 - CONFIDENTIAL TREATMENT REQUESTED
Page 79 - CONFIDENTIAL TREATMENT REQUESTED
Page 80 - CONFIDENTIAL TREATMENT REQUESTED
Page 81 - CONFIDENTIAL TREATMENT REQUESTED
Page 82 - CONFIDENTIAL TREATMENT REQUESTED
Page 83 - CONFIDENTIAL TREATMENT REQUESTED
Page 84 - CONFIDENTIAL TREATMENT REQUESTED
Page 85 - CONFIDENTIAL TREATMENT REQUESTED
Page 86 - CONFIDENTIAL TREATMENT REQUESTED
Page 87 - CONFIDENTIAL TREATMENT REQUESTED
Page 88 - CONFIDENTIAL TREATMENT REQUESTED
Page 89 - Manufacturing and Marketing Rights
Page 90 - CONFIDENTIAL TREATMENT REQUESTED
Page 91 - CONFIDENTIAL TREATMENT REQUESTED
Page 92 - CONFIDENTIAL TREATMENT REQUESTED
Page 93 - CONFIDENTIAL TREATMENT REQUESTED
Page 94 - CONFIDENTIAL TREATMENT REQUESTED
Page 95 - CONFIDENTIAL TREATMENT REQUESTED
Page 96 - CONFIDENTIAL TREATMENT REQUESTED
Page 97 - Schedule 2
Page 98 - Allergan, Inc.
Page 99 - (a)
Page 100 - Quest Group International, Inc. -
Page 101 - Charles River Laboratories, Inc
Page 102 - Donald J. Hayden, Chairman
Page 103 - 401(k) Plan
Page 104 - CONFIDENTIAL TREATMENT REQUESTED
Page 105 - CONFIDENTIAL TREATMENT REQUESTED
Page 106 - CONFIDENTIAL TREATMENT REQUESTED
Page 107 - CONFIDENTIAL TREATMENT REQUESTED
Page 108 - CONFIDENTIAL TREATMENT REQUESTED
Page 109 - CONFIDENTIAL TREATMENT REQUESTED
Page 110 - CONFIDENTIAL TREATMENT REQUESTED
Page 111 - CONFIDENTIAL TREATMENT REQUESTED
Page 112 - CONFIDENTIAL TREATMENT REQUESTED
Page 113 - CONFIDENTIAL TREATMENT REQUESTED
Page 114 - CONFIDENTIAL TREATMENT REQUESTED
Page 115 - CONFIDENTIAL TREATMENT REQUESTED
Page 116 - CONFIDENTIAL TREATMENT REQUESTED
Page 117 - CONFIDENTIAL TREATMENT REQUESTED
Page 118 - CONFIDENTIAL TREATMENT REQUESTED
Page 119 - CONFIDENTIAL TREATMENT REQUESTED
Page 120 - CONFIDENTIAL TREATMENT REQUESTED
Page 121 - CONFIDENTIAL TREATMENT REQUESTED
Page 122 - CONFIDENTIAL TREATMENT REQUESTED
Page 123 - CONFIDENTIAL TREATMENT REQUESTED
Page 124 - CONFIDENTIAL TREATMENT REQUESTED
Page 125 - CONFIDENTIAL TREATMENT REQUESTED
Page 126 - CONFIDENTIAL TREATMENT REQUESTED
Page 127 - CONFIDENTIAL TREATMENT REQUESTED
Page 128 - CONFIDENTIAL TREATMENT REQUESTED
Page 129 - CONFIDENTIAL TREATMENT REQUESTED
Page 130 - CONFIDENTIAL TREATMENT REQUESTED
Page 131 - CONFIDENTIAL TREATMENT REQUESTED
Page 132 - CONFIDENTIAL TREATMENT REQUESTED
Page 133 - CONFIDENTIAL TREATMENT REQUESTED
Page 134 - CONFIDENTIAL TREATMENT REQUESTED
Page 135 - CONFIDENTIAL TREATMENT REQUESTED
Page 136 - CONFIDENTIAL TREATMENT REQUESTED
Page 137 - CONFIDENTIAL TREATMENT REQUESTED
Page 138 - CONFIDENTIAL TREATMENT REQUESTED
Page 139 - CONFIDENTIAL TREATMENT REQUESTED
Page 140 - CONFIDENTIAL TREATMENT REQUESTED
Page 141 - CONFIDENTIAL TREATMENT REQUESTED
Page 142 - CONFIDENTIAL TREATMENT REQUESTED
Page 143 - CONFIDENTIAL TREATMENT REQUESTED
Page 144 - CONFIDENTIAL TREATMENT REQUESTED
Page 145 - CONFIDENTIAL TREATMENT REQUESTED
Page 146 - CONFIDENTIAL TREATMENT REQUESTED
Page 147 - CONFIDENTIAL TREATMENT REQUESTED
Page 148 - CONFIDENTIAL TREATMENT REQUESTED
Page 149 - Schedule 1.1(c)
Page 150 - to our knowledge
Page 151 - Contractual Obligations
Page 152 - N/A
Page 153 - N/A
Page 154 - Series A-2 Preferred
Page 155 - N/A
Page 156 - CONFIDENTIAL TREATMENT REQUESTED
Page 157 - CONFIDENTIAL TREATMENT REQUESTED
Page 158 - CONFIDENTIAL TREATMENT REQUESTED
Subdocument 4 - EX-10.8 - EX-10.8
Page 1 - Exhibit 10.8
Page 2 - CONFIDENTIAL TREATMENT REQUESTED
Page 3 - CONFIDENTIAL TREATMENT REQUESTED
Subdocument 5 - EX-10.10 - EX-10.10
Page 1 - Exhibit 10.10
Page 2 - CONFIDENTIAL TREATMENT REQUESTED
Page 3 - CONFIDENTIAL TREATMENT REQUESTED
Page 4 - CONFIDENTIAL TREATMENT REQUESTED
Page 5 - CONFIDENTIAL TREATMENT REQUESTED
Page 6 - CONFIDENTIAL TREATMENT REQUESTED
Page 7 - CONFIDENTIAL TREATMENT REQUESTED
Page 8 - CONFIDENTIAL TREATMENT REQUESTED
Page 9 - CONFIDENTIAL TREATMENT REQUESTED
Page 10 - CONFIDENTIAL TREATMENT REQUESTED
Page 11 - CONFIDENTIAL TREATMENT REQUESTED
Page 12 - CONFIDENTIAL TREATMENT REQUESTED
Page 13 - CONFIDENTIAL TREATMENT REQUESTED
Page 14 - CONFIDENTIAL TREATMENT REQUESTED
Page 15 - CONFIDENTIAL TREATMENT REQUESTED
Page 16 - CONFIDENTIAL TREATMENT REQUESTED
Page 17 - CONFIDENTIAL TREATMENT REQUESTED
Page 18 - CONFIDENTIAL TREATMENT REQUESTED
Page 19 - CONFIDENTIAL TREATMENT REQUESTED
Page 20 - CONFIDENTIAL TREATMENT REQUESTED
Page 21 - CONFIDENTIAL TREATMENT REQUESTED
Page 22 - CONFIDENTIAL TREATMENT REQUESTED
Page 23 - CONFIDENTIAL TREATMENT REQUESTED
Page 24 - CONFIDENTIAL TREATMENT REQUESTED
Page 25 - CONFIDENTIAL TREATMENT REQUESTED
Page 26 - CONFIDENTIAL TREATMENT REQUESTED
Page 27 - CONFIDENTIAL TREATMENT REQUESTED
Page 28 - CONFIDENTIAL TREATMENT REQUESTED
Page 29 - CONFIDENTIAL TREATMENT REQUESTED
Page 30 - CONFIDENTIAL TREATMENT REQUESTED
Page 31 - CONFIDENTIAL TREATMENT REQUESTED
Page 32 - CONFIDENTIAL TREATMENT REQUESTED
Page 33 - CONFIDENTIAL TREATMENT REQUESTED
Page 34 - CONFIDENTIAL TREATMENT REQUESTED
Page 35 - CONFIDENTIAL TREATMENT REQUESTED
Page 36 - CONFIDENTIAL TREATMENT REQUESTED
Page 37 - CONFIDENTIAL TREATMENT REQUESTED
Page 38 - CONFIDENTIAL TREATMENT REQUESTED
Page 39 - CONFIDENTIAL TREATMENT REQUESTED
Page 40 - CONFIDENTIAL TREATMENT REQUESTED
Page 41 - CONFIDENTIAL TREATMENT REQUESTED
Page 42 - CONFIDENTIAL TREATMENT REQUESTED
Page 43 - CONFIDENTIAL TREATMENT REQUESTED
Page 44 - CONFIDENTIAL TREATMENT REQUESTED
Page 45 - CONFIDENTIAL TREATMENT REQUESTED
Page 46 - CONFIDENTIAL TREATMENT REQUESTED
Page 47 - CONFIDENTIAL TREATMENT REQUESTED
Page 48 - CONFIDENTIAL TREATMENT REQUESTED
Page 49 - CONFIDENTIAL TREATMENT REQUESTED
Page 50 - CONFIDENTIAL TREATMENT REQUESTED
Page 51 - CONFIDENTIAL TREATMENT REQUESTED
Page 52 - CONFIDENTIAL TREATMENT REQUESTED
Page 53 - CONFIDENTIAL TREATMENT REQUESTED
Page 54 - CONFIDENTIAL TREATMENT REQUESTED
Page 55 - CONFIDENTIAL TREATMENT REQUESTED
Page 56 - CONFIDENTIAL TREATMENT REQUESTED
Page 57 - CONFIDENTIAL TREATMENT REQUESTED
Page 58 - CONFIDENTIAL TREATMENT REQUESTED
Page 59 - CONFIDENTIAL TREATMENT REQUESTED
Page 60 - CONFIDENTIAL TREATMENT REQUESTED
Page 61 - CONFIDENTIAL TREATMENT REQUESTED
Page 62 - CONFIDENTIAL TREATMENT REQUESTED
Page 63 - CONFIDENTIAL TREATMENT REQUESTED
Page 64 - CONFIDENTIAL TREATMENT REQUESTED
Page 65 - CONFIDENTIAL TREATMENT REQUESTED
Page 66 - CONFIDENTIAL TREATMENT REQUESTED
Page 67 - CONFIDENTIAL TREATMENT REQUESTED
Page 68 - CONFIDENTIAL TREATMENT REQUESTED
Page 69 - CONFIDENTIAL TREATMENT REQUESTED
Page 70 - CONFIDENTIAL TREATMENT REQUESTED
Page 71 - CONFIDENTIAL TREATMENT REQUESTED
Page 72 - CONFIDENTIAL TREATMENT REQUESTED
Page 73 - CONFIDENTIAL TREATMENT REQUESTED
Page 74 - CONFIDENTIAL TREATMENT REQUESTED
Page 75 - CONFIDENTIAL TREATMENT REQUESTED
Page 76 - CONFIDENTIAL TREATMENT REQUESTED
Page 77 - CONFIDENTIAL TREATMENT REQUESTED
Page 78 - CONFIDENTIAL TREATMENT REQUESTED
Page 79 - CONFIDENTIAL TREATMENT REQUESTED
Page 80 - CONFIDENTIAL TREATMENT REQUESTED
Page 81 - CONFIDENTIAL TREATMENT REQUESTED
Page 82 - CONFIDENTIAL TREATMENT REQUESTED
Page 83 - CONFIDENTIAL TREATMENT REQUESTED
Page 84 - CONFIDENTIAL TREATMENT REQUESTED
Page 85 - CONFIDENTIAL TREATMENT REQUESTED
Page 86 - CONFIDENTIAL TREATMENT REQUESTED
Page 87 - CONFIDENTIAL TREATMENT REQUESTED
Page 88 - CONFIDENTIAL TREATMENT REQUESTED
Page 89 - CONFIDENTIAL TREATMENT REQUESTED
Page 90 - CONFIDENTIAL TREATMENT REQUESTED
Page 91 - CONFIDENTIAL TREATMENT REQUESTED
Subdocument 6 - EX-23.1 - EX-23.1
Page 1 - Exhibit 23.1
Page 2 - N/A